Drug Development

A landmark review decodes how ketogenic diets treat epilepsy, highlighting a major research gap and sparking a quest for drugs that mimic the diet's effects.

Theriva Biologics pushes its promising cancer virus toward pivotal trials, but an auditor's 'going concern' warning raises questions about its future.

Ratio Therapeutics appoints Dr. Colin Hayward as CMO, a strategic move to advance its sarcoma trial and challenge leaders in the booming radiopharmaceutical market.

A new clinical trial begins for APAC, a first-in-class drug aiming to prevent amputation and death from severe peripheral artery disease.

Biotech leader H. Martin Seidel joins Odyssey's SAB, a strategic move signaling accelerated development in the competitive autoimmune disease space.

With its novel glaucoma drug QLS-111 entering Phase 3, Qlaris Bio brings in seasoned leader Fred Guerard to navigate the final trials and path to market.

Edgewise Therapeutics' drug sevasemten shows unprecedented functional stability in Becker muscular dystrophy, a pivotal shift for a disease with no treatments.

French pharma giant Servier acquires Day One Biopharmaceuticals, gaining a breakthrough pediatric cancer drug and signaling a major push into rare oncology.

A new drug for Raynaud's phenomenon in scleroderma patients significantly boosts attack-free days, offering hope despite missing its primary trial goal.

With a strong cash position, ArriVent pushes its lead lung cancer drug toward a mid-2026 data readout while building a new pipeline in ADCs.

Kura Oncology's new AML drug, KOMZIFTI, sees rapid market uptake, strong financials, and an ambitious plan to reshape targeted cancer therapy.

Early data for zolucatetide shows it shrinks tumors in a rare genetic disease, cracking a long-undruggable cancer target and offering new hope.

A NY startup is using quantum computing and AI to fight aging at its source. Can Allosteric Bioscience's high-tech approach unlock a longer, healthier life?

With strong revenue growth and critical FDA decisions on the horizon, MannKind's leadership prepares to outline its vision for investors in Miami.

After solving a key manufacturing flaw, CervoMed advances its promising dementia drug, neflamapimod, to a Phase 3 trial with an optimized dose.

With its lead drug for a rare blood cancer nearing European submission, Cellectar Biosciences advances its targeted radiotherapy platform on two fronts.

Immunome announces stellar Phase 3 data for its desmoid tumor drug, varegacestat, and details a robust, well-funded ADC pipeline aimed at solid tumors.

The D.C. transplant institute surpasses a historic milestone, pioneering new tech and giving thousands a second chance at life amid a national organ shortage.

A new partnership leverages advanced AI and metabolomics to find novel drug targets for rare metabolic disorders, offering new hope for millions worldwide.

A novel drug delivery system could revolutionize Alzheimer's treatment, and Acumen Pharmaceuticals is leading the charge with its targeted therapy.